Michael B. Atkins MD at Georgetown Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology discusses how to select between different combinations of immuno-oncology and TKIs that are available and for the treatment of 1st line renal cell carcinoma (RCC).
